Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE

Immunotherapy ◽  
2017 ◽  
Vol 9 (13) ◽  
pp. 1067-1069
Author(s):  
Malkhaz Mizandari ◽  
Natela Paksashvili ◽  
Nino Kikodze ◽  
Tamta Azrumelashvili ◽  
Ia Pantsulaia ◽  
...  
2021 ◽  
Vol 37 ◽  
pp. 101526
Author(s):  
Sohan Lal Solanki ◽  
Jasmeen Kaur ◽  
Amit M. Gupta ◽  
Shraddha Patkar ◽  
Riddhi Joshi ◽  
...  

2021 ◽  
Vol 83 (5) ◽  
pp. 431-435
Author(s):  
Seiko NAITO ◽  
Taisuke KANNO ◽  
Osamu YAMASAKI ◽  
Shin MORIZANE ◽  
Hayato NOMURA ◽  
...  

2019 ◽  
Vol 52 (3) ◽  
pp. 103
Author(s):  
I-Shu Chen ◽  
Chao-Chien Hung ◽  
Tsung-Jung Liang ◽  
Huai-Pao Lee

2020 ◽  
Vol 32 (4) ◽  
pp. 265-271
Author(s):  
Takeshi MARUMORI ◽  
Kazuhiro HIYAMA ◽  
Taichi MAFUNE ◽  
Hisashi HORIGUCHI ◽  
Kohei OHNO ◽  
...  

2014 ◽  
Vol 61 (2) ◽  
pp. 47-49
Author(s):  
Nadezda Basara

Background: Unresectable colorectal liver metastases can be resected after response to chemotherapy. The use of neoadjuvant chemotherapy with or without targeted monoclonal antibodies increases the proportion of resectable liver metastasis and conferred a long term survival of 40%. Methods: The current ongoing studies regarding neodjuvant treatment strategies aiming to increase a proportion of patients with resectable liver metastases is going to be presented. Results: Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression free survival in resected patients. The results of the CELIM study confirm a favourable long-term survival for patients with initially suboptimal or unresectable colorectal liver metastasis who respond to conversion therapy and undergo secondary resection. The New EPOC randomised trial does not support the addition of cetuximab to chemotherapy and surgery for operable colorectal liver metastasis in KRAS exon 2 wild-type patients. Conclusion: The ability of anti-epidermal growth factor receptor agents to increase response rate and resection when added to chemotherapy has been clearly shown in a number of trials. The resection rates are higher with chemotherapy plus Cetuximab, in general, a conversion is contributes to the better overall survival.


HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S308
Author(s):  
E. Gasser ◽  
E. Braunwarth ◽  
B. Cardini ◽  
N. Fadinger ◽  
M. Maglione ◽  
...  

1994 ◽  
Vol 5 (8) ◽  
pp. 465-472 ◽  
Author(s):  
J. R. Dorin ◽  
B. J. Stevenson ◽  
S. Fleming ◽  
E. W. F. W. Alton ◽  
P. Dickinson ◽  
...  

2011 ◽  
Vol 44 (12) ◽  
pp. 1543-1549
Author(s):  
Yoshiro Chijiiwa ◽  
Hitosi Ichimiya ◽  
Shuichi Kurihara ◽  
Nobushige Yamagata ◽  
Koutaro Matsumoto ◽  
...  

2003 ◽  
Vol 64 (5) ◽  
pp. 1217-1220
Author(s):  
Satoru YANAGISAWA ◽  
Yoshifumi SANO ◽  
Tomoyoshi OKAMOTO ◽  
Tokuyasu YOKOTA ◽  
Sumio TAKAYAMA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document